GlassScriptPhysician profile
Jose A Manuel
NPI 1558625863
$3,487.37
in general payments reported to CMS, 2019-2025
22 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $364 · 2022: $772 · 2023: $1,074 · 2024: $751 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,352.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $469.80 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $443.57 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $402.83 | 2022-2024 | |
| Pfizer INC. | $351.54 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $324.71 | 2022-2025 | |
| Exact Sciences Corporation | $302.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $238.50 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $206.29 | 2021-2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.03 | 2022-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $165.82 | 2021-2025 | Airsupra, Breztri |
| Abbvie INC. | $118.79 | 2021-2023 | |
| Daiichi Sankyo INC. | $64.13 | 2022-2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.18 | 2024 | |
| Philips North America LLC | $36.51 | 2024 | (Ck7) Extended Holter |
| Biohaven Pharmaceutical Holding Company LTD. | $22.10 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $20.79 | 2023 | Wellbutrin, Aplenzin |
| Vertos Medical, INC. | $20.61 | 2024 | Mild Device Kit |
| Amarin Pharma, INC. | $17.53 | 2021 | |
| Nevro Corp. | $16.07 | 2023 | Senza |
| Biohaven Pharmaceuticals, INC. | $14.83 | 2021 | |
| Corcept Therapeutics | $13.79 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $13.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Manuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.